Elicio Therapeutics Analysis: $89M Raised
What is Elicio Therapeutics?
Lymph node-targeted immunotherapies for cancer
Product Features & Capabilities
- AMP platform for cancer immunotherapy
- ELI-002
- ELI-007
- ELI-008
- next-generation vaccines
- immunomodulators
- adjuvants
Investment Focus
Elicio Therapeutics primarily focuses on developing cancer immunotherapies aimed at solid tumors, with a particular emphasis on challenging cancers such as pancreatic ductal adenocarcinoma (PDAC).
Key Innovations
- AMP Platform
- ELI-002 - A personalized cancer vaccine that aims to enhance the immune response against tumors, particularly in challenging cancers like pancreatic ductal adenocarcinoma (PDAC).
- Novel Immunotherapies - Elicio is focused on developing a pipeline of novel immunotherapies for the treatment of various cancers, leveraging their unique technology and research.
Partnerships
Elicio Therapeutics has established several significant partnerships and collaborations in the biotech industry, including: 1. A clinical supply agreement with Regeneron to evaluate the safety and efficacy of ELI-002 in combination with Libtayo (cemiplimab) for KRAS-driven tumors. 2. A collaboration with Natera to conduct a Phase I/II study of ELI-002 in pancreatic cancer. 3. A partnership with the Moffitt Cancer Center to study AMP-CD19 in combination with CD19 CAR-T cells.
These collaborations aim to enhance the development and application of Elicio's immunotherapy products.
